Google News
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases Business WireGilead to acquire immunology biotech, offers lifeline to G...
Source: Google News
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases Business WireGilead to acquire immunology biotech, offers lifeline to Galapagos statnews.comGilead bets $1.68B upfront on Ouro Medicines’ autoimmune program, with Galapagos expected to pitch in Endpoints NewsGilead Sciences buys autoimmune biotech Ouro Medicines for $2.2bn Financial TimesGilead's $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos Fierce Biotech